Magainin Pharmaceuticals Inc. of Plymouth Meeting, Pa., saidThursday it is beginning Phase I clinicals for its broad-spectrum topical anti-bacterial and anti-fungal drug, MSI-78.Preclinical tests showed the drug to be effective against abroad spectrum of bacteria and fungi associated with skininfections, the company said.

(c) 1997 American Health Consultants. All rights reserved.